Efficacy and effects of Entrectinib

Entrectinib (Entrectinib) is an anti-tumor drug that targets specific gene mutations and belongs to the class of multi-target tyrosine kinase inhibitors (TKI). Its main efficacy and role involve the treatment of tumors such as neuroblastoma, ROS1 gene fusion and ALK gene fusion-positive non-small cell lung cancer.

1.Basic principle and mechanism of action: Entrectinib is a small molecule drug that exerts its effects by inhibiting abnormally active tyrosine kinase signaling pathways. It mainly acts on tumor cells carrying specific genetic mutations, inhibiting the growth, division and spread of these cells. Specifically, entrectinib inhibits abnormal signaling caused by mutations such as NTRK gene fusion, ROS1 ROS1 gene fusion, and ALK gene fusion, thus interfering with the survival mechanism of tumor cells and causing tumor cells to die or stop growing.

2.Treatment of neuroblastoma: Neuroblastoma (Neuroblastoma) is a common malignant tumor in children, usually occurring near the adrenal glands. Some neuroblastoma patients carry NTRK gene fusions, which cause abnormal signaling and encourage tumor cell growth. By inhibiting this abnormal signaling pathway, entrectinib can significantly slow down or even inhibit the growth of neuroblastoma, thus providing a new treatment option for these patients.

3. Treatment of ROS1 and ALK positive non-small cell lung cancer: Non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) is one of the most common types of lung cancer. Some NSCLC patients carry ROS1 or ALK gene fusions. These fusions can also lead to abnormal signaling and promote the proliferation and survival of tumor cells. Entrectinib can inhibit the growth of these cells by inhibiting the abnormal activities of ROS1 and ALK, thereby showing significant anti-tumor effects in these patients.

4.Personalized treatment: Entrectinib is unique in that it is a personalized treatment drug. It only exerts an inhibitory effect on tumor cells carrying specific genetic mutations, so genetic testing is needed to confirm whether patients are suitable for this drug. This individualized approach to treatment helps maximize the effectiveness of the medication while reducing unnecessary side effects.

5.Drug Side Effects: Although entrectinib has great potential in targeted therapy, like other drugs, it may also cause some side effects. Common side effects include nausea, vomiting, diarrhea, fatigue, loss of appetite, etc. When using entrectinib, doctors will closely monitor the patient's condition and drug tolerance, and adjust the dose or provide supportive care to reduce side effects if necessary.

In summary, entrectinib, as a multi-target tyrosine kinase inhibitor, exerts an inhibitory effect on tumor cells with specific gene mutations, significantly providing a treatment option for patients with neuroblastoma and ROS1/ALK positive non-small cell lung cancer. Its personalized treatment strategy and potential to fight tumors make it an important advance in the field of cancer treatment. However, it should be noted that the application of drugs still needs to be carried out under the guidance of a doctor to ensure the best therapeutic effect and patient safety.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.